Laminin α2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: A model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasis

American Journal of Pathology

Volumn 168, Issue 3, 2006, Pages 991-1003

  Vitolo, Domenico ^a,c   Ciocci, Luciano ^a   Deriu, Gloria ^a   Spinelli, Silvia ^a   Cortese, Stefania ^a   Masuelli, Laura ^a   Morrone, Stefania ^a   Filice, Mary Jo ^a   Coloni, Giorgio Furio ^a   Natali, Pier Giorgio ^b   Baroni, Carlo Davide ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Department of Experimental Medicine and Pathology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; LAMININ; LAMININ ALPHA2; LAMININ BETA1; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 6; MONOCLONAL ANTIBODY;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER INVASION; CARCINOID; CELL MIGRATION; ENDOTHELIUM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; METASTASIS; MONOLAYER CULTURE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOLOGICAL MODEL; CAPILLARY; CARCINOMA; CELL MOTION; CHEMISTRY; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; CAPILLARIES; CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; HUMANS; LAMININ; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; UP-REGULATION;

EID: 33644644438     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.041310     Document Type: Article

References (51)

1. Patarroyo M, Tryggvason K, Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002, 12:197-207
2. Sorokin LM, Paush F, Frieser M, Kroger S, Ohage E, Deutzmann R: Developmental regulation of the laminin α5 chain suggests a role in epithelial and endothelial cell maturation. Dev Biol 1997, 189:285-300
3. Kikkawa Y, Sanzen N, Sekiguchi K: Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells-laminin-10/11 mediates cell adhesion through integrin α3β1. J Biol Chem 1998, 25:15854-15859
4. Tani T, Lehto VP, Virtanen I: Expression of laminins 1 and 10 in carcinoma cells and comparison of their roles in cell adhesion. Exp Cell Res 1999, 248:115-121
5. Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K: Expression of the gamma(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin Cancer Res 2001, 7:896-900
6. Lohi J: Laminin-5 in the progression of carcinomas. Int J Cancer 2001, 94:763-767
7. Leivo I, Engvall E: Merosin, a protein specific for basement membranes of Schwann cells, striate muscle and trophoblast, is expressed late in nerve and muscle development. Proc Natl Acad Sci USA 1988, 85:1544-1561
8. Leivo I, Engvall E, Laurila P, Miettinen M: Distribution of merosin, a laminin-related tissue-specific basement membrane protein, in human Schwann cell neoplasms. Lab Invest 1989, 61:426-432
9. Ehrig K, Leivo I, Agraves WS, Ruoslahti E, Engvall E: Merosin, a tissue specific basement membrane protein, is a laminin-like protein. Proc Natl Acad Sci USA 1990, 87:3264-3268
10. Damsky CH, Fitzgeraald ML, Fischer SJ: Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway in vivo. J Clin Invest 1992, 89:210-222
11. Vachon PH, Loechel F, Xu H, Wewer UM, Engvali E: Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J Cell Biol 1996, 134:1483-1497
12. Miyagoe-Suzuki Y, Nakagawa M, Takeda S: Merosin and congenital muscular dystrophy. Microsc Res Tech 2000, 48:181-191
13. Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 1996, 28:521-528
14. Vitolo D, Ciocci L, Cicerone E, Rossi C, Tiboni F, Ferrauti P, Gallo A, Baroni CD: Laminin α2 chain (merosin M chain) distribution and VEGF, FGF2 and TGFβ1 gene expression in angiogenesis of supraglottis, lung and breast carcinomas. J Pathol 2001, 195:197-208
15. Gupta MK, Qin RY: Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003, 9:1144-1155
16. Decaussin M, Sartelet H, Robert C, Moro D, Clara ZC, Brambilla C, Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-FLT1 and VEGF-R2-KDR) in non-small cell lung carcinomas: correlation with angiogenesis and survival. J Pathol 1999, 188:369-377
17. Vesweber D: Molecular mechanisms that control endothelial cell contacts. J Pathol 2000, 190:281-291
18. Colby TV, Koss MN, Travis WD: Tumors of the lower respiratory tract. Atlas of Tumor Pathology, third series, fascicle 13. Washington DC, Armed Forces Institute of Pathology, 1995:235-315
19. Mills SE, Gaffey M, Frierson HF: Tumors of the upper aerodigestive tract and ear. Atlas of Tumor Pathology, third series, fascicle 26. Washington DC, Armed Forces Institute of Pathology, 2000:45-117
20. Roset PP, Oberman HA; Tumors of the mammary gland. Atlas of Tumor Pathology, third series, fascicle 7. Washington DC, Armed Forces Institute of Pathology, 1993:157-244
21. Travis TW, Colby V, Corrin B, Shimosato Y, Brambilla E: In Collaboration with Sobin LH and Pathologists in 14 Countries. Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin, Germany: Springer-Verlag, 1999
22. Meri S, Mattila P, Renkonen R: Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur J Immunol 1993, 23:2511-2516
23. Bei R, Masuelli L, Moriconi E, Visco V, Moretti A, Kraus MH, Muraro R: Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 1999, 18:1267-1275
24. Pouliot N, Nice EC, Burgess AW: Laminin-10 mediate basal and EGF-stimulate motility of human colon carcinoma cells via alpha (3) beta (1) and alpha (6) beta (4) integrins. Exp Cell Res 2001, 266:1-10
25. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422-433
26. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410:83-86
27. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerizaton in development and cancer. EMBO J 2000, 19:3159-3167
28. Damstrup L, Rude Voldborg B, Spang-Thomsen M, Brunner N, Skovgaard Poulsen H: In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 1998, 78:631-640
29. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ: Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832
30. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck. Cancer Res 1993, 53:3579-3584
31. Deugnier MA, Faraldo MM, Janji B, Rousselle P, Thiery JP, Glukhova MA: EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. J Cell Biol 2002, 159:453-463
32. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-2385
33. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA: Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002, 41:124-130
34. Damstrup L, Pedersen Wandahl M, Bastholm L, Elling F, Poulsen Skovgaard H: Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 2002, 97:7-14
35. Shimizu T, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F: Growth characteristics of rectal carcinoid tumors. Oncology 2000, 59:229-237
36. Franklin WA, Veve R, Hirsh FR, Helfrich BA, Bunn Jr PA: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29:3-14
37. Bello-DeOcampo D, Kleinmann HK, Webber MM: The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelium. Mutat Res 2001, 480-481:209-217
38. Poullot N, Connoly LM, Moritz RC, Simpson RJ, Burgess WA: Colon cancer cells adhesion and spreading on autocrine laminin-10 is mediated by multiple integrin receptors and modulated by EGF receptor stimulation. J Pathol 1999, 188:361-368
39. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4:121-133
40. Kawano Y, Nakamura S, Nasu K, Narahara H, Miyakawa I: Effect of epidermal growth factor on vascular endothelial growth factor secretion by endometrial stromal cells. Clin Exp Med 2002, 2:69-75
41. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7:2-8
42. Bookman MA, Darcy KM, Pearson-Clarke D, Boothby RA, Horowitz IR: Evaluation on monoclonal humanized anti-HER 2 antibody, Trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal cafcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290
43. Fujiuchi S, Ohsaky, Kikuchi K: Suramin inhibits the growth of non-small-cell cancer cells that express the epidermal growth factor receptor. Oncology 1997, 54:134-140
44. Bunn Jr PA, Franklin W: Epidermal growth factor receptor expression, signal pathway inhibitors in non-small cell lung cancer. Semin Oncol 2002, 29:38-44
45. Gainet M, Guardioia E, Dufresne A, Pivot X: Epidermal growth factor receptors (EGFR): a new target for anticancer therapy. Cancer Radiother 2003, 7:195-199
46. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599
47. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59:5209-5218
48. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:15-24
49. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398
50. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434
51. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil(FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65